October 5, 2017 / 9:04 PM / 18 days ago

Lilly wins Alimta patent dispute in U.S.

(Reuters) - The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co in a patent dispute over its cancer drug Alimta with Neptune Generics LLC and Sandoz Inc.

Alimta, Lilly’s top-selling oncology treatment, generated sales of $2.3 billion last year.

Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below